7 research outputs found

    Quality of Life related to health in the morbidity of periodic hemodialysis patient

    Get PDF
    Foundation: chronic renal failure has a negative impact in the quality of life and constitutes a morbidity predictor in patients with periodic hemodialysis.Objective: to evaluate the influence of quality of life related to health in the morbidity of patients in intermittent periodic hemodialysis.Methods: a descriptive study was done in patients with three or more time of intermittent periodic hemodialysis at the Nephrology service of the Military Hospital Dr. Carlos J. Finlay. Havana, in a 12 month follow up period. The variables analyzed were: age, sex, time with the substituting renal function treatment, morbidity rate, type of morbidity in hemodialysis and hospital admission rate. A questionnaire for quality of life in patients with renal disease (version 1.3) was applied.Results: patients under 60 years old predominated, of high schooling level, with blood hypertension mainly due to renal failure.  The most frequent morbidities were: chills, arterial Hypotension, and complications related to vascular access. The admission rate was low. The summary physical component had the lower punctuation followed by the summary mental component. Among these and age there was found an inversely proportional correlation, so as the morbidity rate and the summary physical component.Conclusion: the results obtained are related to preceding studies. The physical component summary results with higher involvement, mainly in the older adult, considering the negative relation with the morbidity rate and hospital admission.</p

    Characterization of participants adolescents in the clinical trial with Abdala vaccine

    Get PDF
    Introduction: The clinical evaluation of anti-COVID-19 vaccines in pediatric population, is a challenge in times of pandemic, to respond to the urgency of representative samples that contribute to the reproducibility of the study in the real population. Objective: To characterize the adolescents participating in the clinical trial with the Abdala anti-COVID-19 vaccine, to evaluate compliance with the vaccination schedule and to estimate whether they are representative of this population group. Methods: Data from a phase II trial with Abdala vaccine were used. A total of 703 subjects were included, 207 (29.4 %) of them were adolescents, between 12 and 18 years of age, with apparently healthy or controlled chronic diseases, nutritional assessment between 10 and 90 percentiles, and willingness to participate in the study. Sociodemographic data, personal pathological history, toxic habits and compliance with the vaccination scheme of 3 doses every 14 days were the variables studied. Results: The average age was 15 years, it was predominant female sex (51.7 %), white skin color (55.6 %) and nutritional assessment above 75 to 90 percentiles (40.6 %). The 9.6 % had toxic habits such as smoking and ingestion of alcoholic beverages. Some personal pathological history was in 51.2 % with a higher prevalence for bronchial asthma, rhinitis and other allergies. The vaccination scheme was fulfilled for 95.8 % of individuals. Conclusions: Sociodemographic characteristics, pathological history and toxic habits described for adolescents on the study are representative for this population group in Cuba. The vaccination schedule had an optimal compliance

    Efficacy of nimotuzumab according to inflammatory indices in patients with advanced non-small cell lung cancer

    Get PDF
    Introduction: The response to therapies in advanced lung cancer could be related to certain prognostic factors such as inflammatory indices. Objective: To evaluate the efficacy of the humanized monoclonal antibody nimotuzumab in patients with advanced non-small cell lung cancer according to inflammatory indices. Method: A retrospective longitudinal evaluation study was carried out in a universe of 498 patients older than 18 years, with a cytohistological diagnosis of non-small cell lung cancer, in advanced stages, after the first line of oncological therapy, including in multicenter clinical trials promoted by the Center for Molecular Immunology from 2002 to 2018. Descriptive statistics were applied, the x-tile 3.6.1 software was used for the Kaplan Meier test, significant differences were considered when p< 0,05. Results: In the patients analyzed, nimotuzumab showed therapeutic benefit in the group of patients who did not progress to the first line of treatment with chemotherapy or chemoradiotherapy, when they had a lower neutrophil-lymphocyte index (p= 0,017 and p= 0,027) and a lower platelet-lymphocyte index (p= 0,030 and p= 0,009). Conclusion: Selecting a patient with a lower inflammatory index benefits the efficacy of treatment with the humanized mAb nimotuzumab in advanced non-small cell lung cancer, which becomes a predictive tool for response to treatment

    Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP

    Get PDF
    Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014–2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6–8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn’s Disease activity index [wPCDAI] 15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6–8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn’s disease regardless of the location of disease and disease activityS

    Towards a framework for communication evidence

    No full text
    This article attempts to construct a mid-level theoretical overview of communication evidence (sometimes referred to as 'forensic linguistics'), using decision trees as a theoretical framework. It suggests that there are three main issues - the nature of the sample, the type of evidence and the analysis used. The types of evidence are categorised into language crimes, tradenames, meaning transfer and author attribution, and examples and discussion are given for each. They are further subcategorised, and distinguishing features and characteristics are discussed. It is suggested that the type of analysis used to provide linguistic evidence needs to take into account simultaneously the method of analysis and the communication systems involved. Communication systems in turn are categorised according to 'levels' and variable features. This article is regarded as programmatic rather than conclusive - it is intended to stir debate, rather than be seen as a firm statement

    Quality of Life related to health in the morbidity of periodic hemodialysis patient

    Get PDF
    Foundation: chronic renal failure has a negative impact in the quality of life and constitutes a morbidity predictor in patients with periodic hemodialysis.Objective: to evaluate the influence of quality of life related to health in the morbidity of patients in intermittent periodic hemodialysis.Methods: a descriptive study was done in patients with three or more time of intermittent periodic hemodialysis at the Nephrology service of the Military Hospital Dr. Carlos J. Finlay. Havana, in a 12 month follow up period. The variables analyzed were: age, sex, time with the substituting renal function treatment, morbidity rate, type of morbidity in hemodialysis and hospital admission rate. A questionnaire for quality of life in patients with renal disease (version 1.3) was applied.Results: patients under 60 years old predominated, of high schooling level, with blood hypertension mainly due to renal failure.  The most frequent morbidities were: chills, arterial Hypotension, and complications related to vascular access. The admission rate was low. The summary physical component had the lower punctuation followed by the summary mental component. Among these and age there was found an inversely proportional correlation, so as the morbidity rate and the summary physical component.Conclusion: the results obtained are related to preceding studies. The physical component summary results with higher involvement, mainly in the older adult, considering the negative relation with the morbidity rate and hospital admission.</p

    Farmacovigilancia intensiva de vacunas SOBERANA®02 y Soberana®Plus en población pediátrica en el Centro de Inmunología Molecular

    No full text
    Las vacunas SOBERANA®02 y SOBERANA® Plus contra el coronavirus tipo 2 causante del síndrome respiratorio agudo severo, recibieron autorización de uso en emergencia por la autoridad reguladora de Cuba, y de inmediato aconteció una campaña de vacunación masiva en población pediátrica, lo que devino en una inminente movilización de centros de vacunación y vigilancia de sus eventos adversos. El Centro de Inmunología Molecular realizó un estudio de farmacovigilancia intensiva que evalúo el cumplimiento del esquema heterólogo con ambas vacunas, su seguridad y la incidencia de casos positivos a COVID-19 en niños y adolescentes después de completar el esquema de inmunización. Desde el 15 de septiembre al 31 de diciembre del 2021, participaron 529 sujetos entre 2 y 18 años de edad, de ambos sexos, sin antecedentes de infección por coronavirus tipo 2 del síndrome respiratorio agudo severo, procedentes de 35 municipios y 12 provincias cubanas, quienes recibieron vacuna SOBERANA®02 (dos dosis) y SOBERANA®Plus (una dosis). Se realizó vigilancia de eventos adversos hasta 30 días después de la última dosis recibida. Se consultó la plataforma informática nacional Higia Andariego para identificar los casos positivos al virus del síndrome respiratorio agudo severo coronavirus 2, hasta 3 meses de haber completado la vacunación. El 98,5% de los participantes completó el esquema de vacunación y en el 6,6% se notificó algún evento adverso con relación consistente a la vacunación. Predominaron las reacciones locales (dolor, eritema, inflamación), sobre las reacciones sistémicas (fatiga y febrícula), de intensidad ligera o moderada. Se logró un elevado cumplimiento del esquema de inmunización, con un perfil de seguridad favorable, los sujetos con esquema completo de inmunización no enfermaron de COVID-19
    corecore